Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G for CytomX Therapeutics, Inc. Common Stock, par value $0.00001 per share (CTMX).
- Disclosed ownership: 5.4%.
- Date of event: 30 Jun 2025.
ORBIMED ADVISORS LLC - 30 Jun 2025 SCHEDULE 13G Report for CytomX Therapeutics, Inc. Common Stock, par value $0.00001 per share (CTMX)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- OrbiMed Advisors LLC
- Symbol
- CTMX
- Shares outstanding
- 156,694,444 shares
- Disclosed Ownership
- 8,461,500 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Aug 2025, 18:07:11 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 5.4% ownership in CytomX Therapeutics, Inc. Common Stock, par value $0.00001 per share (CTMX) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 18:07.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 5.4% | 8,461,500 | 0 | 8,461,500 | /s/ Carl L. Gordon | Carl L. Gordon / Member of OrbiMed Advisors LLC |